Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer-Reference-Cited by-同舟云学术

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer

Published:2020-06 Issue: Volume:132 Page:211-223
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Facchinetti Francesco,Lacroix Ludovic,Mezquita Laura,Scoazec Jean-Yves,Loriot Yohann,Tselikas Lambros,Gazzah Anas,Rouleau Etienne,Adam Julien,Michiels Stefan,Massard Christophe,André Fabrice,Olaussen Ken A.,Vassal Gilles,Howarth Karen,Besse Benjamin,Soria Jean-Charles,Friboulet Luc^ORCID,Planchard David

Funder

European Research Council

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

2. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin Canc Res,2013

3. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer;Mok;N Engl J Med,2017

4. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers;Katayama;Sci Transl Med,2012

5. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer;Friboulet;Canc Discov,2014

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma;Cell Reports Medicine;2024-08

2. SIRT7 promotes mitochondrial biogenesis to render the adaptive resistance to MAPK inhibition in melanoma;Biochemical and Biophysical Research Communications;2024-08

3. Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy;Frontiers in Oncology;2024-07-15

4. Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib;Frontiers in Oncology;2024-07-08

5. Pathways and targeting avenues of BRAF in non-small cell lung cancer;Expert Opinion on Therapeutic Targets;2024-07-02